Detalhes bibliográficos
Ano de defesa: |
2014 |
Autor(a) principal: |
Mendonça, Cristiano de Queiroz
 |
Orientador(a): |
Cipolotti, Rosana
 |
Banca de defesa: |
Não Informado pela instituição |
Tipo de documento: |
Dissertação
|
Tipo de acesso: |
Acesso aberto |
Idioma: |
por |
Instituição de defesa: |
Universidade Federal de Sergipe
|
Programa de Pós-Graduação: |
Pós-Graduação em Ciências da Saúde
|
Departamento: |
Não Informado pela instituição
|
País: |
BR
|
Palavras-chave em Português: |
|
Palavras-chave em Inglês: |
|
Área do conhecimento CNPq: |
|
Link de acesso: |
https://ri.ufs.br/handle/riufs/3885
|
Resumo: |
Introduction:Acute Lymphoid Leukemia (ALL) is the most frequent cancer in young people and, if analyzed together with Non-Hodgkin Lymphoma (NHL), we find that they are responsible for at least one third of all cases of childhood cancer. Present-day therapeutic protocols include high doses of glucocorticoids (GC), drugs associate with high potential for elevating intraocular pressure (IOP) and, consequently provoking damage to the fibers of the optic nerve fibers, a pathology classified as cortisone glaucoma. In genetically susceptible patients, ocular hypertension normally occurs some weeks into the use of a steroid but is generally reversible with the suspension of its use. However, depending on the levels of ocular pressure and the duration of ocular hypertension, it can result in optic neuropathology and, in extreme cases, blindness. Since ALL and NHL are oncological disorders with elevated potential for cure of young people with have high life expectancy, the identification of eventual long-term treatment complications could give support to a delineation still lacking in scientific literature, that is, an ophthalmological protocol for these cases. Objective: The aim of this study was to evaluate the behavior of intraocular pressure in pediatric patients treated with GC for the acute lymphoproliferative neoplasias that are most common during childhood and adolescence.Methods: A systematic review of the theme was carried out, followed by a descriptive, prospective study of children and adolescents of both sexes who were diagnosed with ALL and NHL, and who were registered for beginning chemotherapeutic treatment at the Dr. Oswaldo Leite Oncology Center of Sergipe. The inclusion criteria were: diagnosis of ALL or NHL-T confirmed by immunophenotyping of bone marrow or peripheral blood samples (ALL), or immunohistochemistry of material obtained by open biopsy (NHL); age less than 19; no previous chemotherapy; absence of previous diagnosis compatible with glaucoma or any other disorder envolving change in intraocular pressure; no systemic use of GC in the six months preceding diagnosis of ALL or NHL. Patients whose evaluation of IOP might not have been technically adequate, as well as those who expired during the follow-up period, were excluded. Intraocular pressure was measured before treatment (D0), on the eighth (D8), the fourteenth (D14) and twentieth (D28) treatment day. The IOP results above 21 mm Hg were considered to be ocular hypertension. Results: Results of the systematic review indicate the need for new studies, for the review found a total of only three published articles whose results varied between total control of ocular pressure and visual function, to irreversible blindness. The results of our field research involved 15 patients, two of them with ocular hypertension, and with a statistically significant difference of measurements of IOP between D0 vs D8 and D0 vs D14 (p=0.013). Conclusion: The possibility of silent ocular hypertension, with the consequent risk of irreversible blindness, indicates the need to assess the introduction of a protocol for verification of IOP in patients recently diagnosed with ALL and NHL, including weekly exams, at least until the complete cessation of GC use. |